Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Treace Medical Concepts to post earnings of ($0.04) per share and revenue of $67.19 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Treace Medical Concepts Price Performance
Shares of TMCI traded down $0.29 during trading hours on Friday, hitting $9.37. 257,560 shares of the company were exchanged, compared to its average volume of 388,687. The company has a market capitalization of $583.75 million, a PE ratio of -9.46 and a beta of 0.75. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.12 and a quick ratio of 2.98. The firm has a fifty day simple moving average of $8.69 and a 200-day simple moving average of $7.12. Treace Medical Concepts has a one year low of $3.92 and a one year high of $14.98.
Wall Street Analyst Weigh In
TMCI has been the subject of several research reports. Stifel Nicolaus raised their price objective on Treace Medical Concepts from $7.00 to $8.00 and gave the stock a "hold" rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $8.00 price objective on shares of Treace Medical Concepts in a report on Tuesday, December 17th. BTIG Research upgraded Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 price objective for the company in a report on Tuesday, February 4th. Lake Street Capital began coverage on shares of Treace Medical Concepts in a research report on Tuesday, December 31st. They set a "buy" rating and a $14.50 target price on the stock. Finally, Truist Financial increased their target price on shares of Treace Medical Concepts from $7.00 to $8.40 and gave the stock a "hold" rating in a research report on Wednesday, December 18th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $9.99.
View Our Latest Stock Report on Treace Medical Concepts
About Treace Medical Concepts
(
Get Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
See Also
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
